Table 1 Number of reports and reporting odds ratios for chemotherapy-induced peripheral neuropathy.

From: Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database

Category	ATC^a code	Drugs	Total (n)	Case (n)	ROR^b (95% CI^c)
Total			622,289	1883
Purine analogues^f	L01BB05	fludarabine	1498	3	0.7 (0.2–2.1)
Purine analogues^f	L01BB07	nelarabine	169	17	37.2 (22.5–61.5)*
Pyrimidine analogues	L01BC02	fluorouracil	8678	116	4.7 (3.9–5.7) *
	L01BC05	Gemcitabine	4939	29	2.0 (1.4–2.8) *
	L01BC06	Capecitabine	4022	46	3.9 (2.9–5.2) *
Vinca alkaloids and analogues	L01CA01	Vinblastine	294	17	20.4 (12.5–33.4) *
	L01CA02	Vincristine	3293	49	5.1 (3.8–6.8) *
	L01CA03	Vindesine	227	2	2.9 (0.7–11.8)
	L01CA04	Vinorelbine	800	4	1.7 (0.6–4.4)
Taxanes	L01CD01	Sorbent-based paclitaxel	6529	231	13.6 (11.9–15.7) *
	L01CD01	Nanoparticle albumin-bound paclitaxel	1673	27	5.5 (3.7–8.0) *
	L01CD02	Docetaxel	7274	40	1.8 (1.3–2.5) *
	L01CD04	Cabazitaxel	1365	9	2.2 (1.1–4.2) *
Anthracyclines and related substances	L01DB01	Doxorubicin	4540	24	1.8 (1.2–2.6) *
Platinum compounds	L01XA01	Cisplatin	9488	32	1.1 (0.8–1.6)
	L01XA02	Carboplatin	6212	87	4.9 (3.9–6.0) *
	L01XA03	Oxaliplatin	8737	491	26.2 (23.6–29.1) *
	–^d	Miriplatin hydrate	312	1	–^e
	–^d	Nedaplatin	581	1	–^e
Monoclonal antibodies	L01XC07	Bevacizumab	11,048	121	3.8 (3.2–4.6) *
	L01XC12	Brentuximab vedotin	652	40	22.0 (15.9–30.4) *
	L01XC17	Nivolumab	8099	54	2.2 (1.7–2.9) *
	L01XC18	Pembrolizumab	4928	35	2.4 (1.7–3.3) *
	L01XC24	Daratumumab	782	32	14.3 (10.0–20.4) *
Protein kinase inhibitors^f	L01XE01	Imatinib	4747	6	0.4 (0.2–0.9)
	L01XE02	Gefitinib	2863	1	–^e
	L01XE04	Sunitinib	3631	3	0.3 (0.1–0.8)
	L01XE05	Sorafenib	5261	5	0.3 (0.1–0.7)
	L01XE06	Dasatinib	1534	3	0.6 (0.2–2.0)
	L01XE07	Lapatinib	753	3	1.3 (0.4–4.1)
	L01XE08	Nilotinib	2056	1	–^e
	L01XE10	Everolimus	4070	3	0.2 (0.1–0.8)
	L01XE11	Pazopanib	1712	2	0.4 (0.1–1.5)
	L01XE14	Bosutinib	390	1	–^e
	L01XE16	Crizotinib	1180	6	1.7 (0.8–3.8)
	L01XE17	Axitinib	1052	2	0.6 (0.2–2.5)
	L01XE18	Ruxolitinib	1172	3	0.8 (0.3–2.6)
	L01XE21	Regorafenib	1957	6	1.0 (0.5–2.3)
	L01XE23	Dabrafenib	312	1	–^e
	L01XE24	Ponatinib	426	3	2.3 (0.8–7.3)
	L01XE25	Trametinib	321	1	–^e
	L01XE27	Ibrutinib	396	1	–^e
	L01XE32	Cediranib	93	4	14.8 (5.4–40.4) *
	L01XE33	Palbociclib	1572	1	–^e
	L01XE44	Lorlatinib	108	9	30.1 (15.2–59.6) *
	L01XE54	Gilteritinib	194	1	–^e
Other antineoplastic agents	L01XX19	Irinotecan	6136	38	2.1 (1.5–2.9) *
	L01XX32	Bortezomib	2727	210	30.8 (26.6–35.8) *
	L01XX50	Ixazomib	893	21	8.0 (5.2–12.4) *
Other immunosuppressants	L04AX02	Thalidomide	362	13	12.4 (7.1–21.5) *
	L04AX04	Lenalidomide	5714	70	4.2 (3.3–5.3)*
	L04AX06	Pomalidomide	1378	3	0.7 (0.2–2.2)

^aATC: Anatomical Therapeutic Chemical.
^bROR: Reporting Odds Ratio.
^cCI: Confidence Interval.
^dATC code has not been assigned.
^eNumber of cases was < 2.
^fAlthough the number of reports was 20 or less, “purine analogues” and “protein kinase inhibitors” were added because the time-to-onset analysis was possible.
*Lower limit of the 95% CI corresponding to the ROR was greater than 1.

Back to article page

Table 1 Number of reports and reporting odds ratios for chemotherapy-induced peripheral neuropathy.

Search

Quick links